Startseite » Research » Research fields » Schizophrenia » Clinical and experimental treatment of schizophrenic psychoses

Clinical and experimental treatment of schizophrenic psychoses

Head:

PD Dr. med. Alkomiet Hasan


The Working Group on Clinical and Experimental Treatment of Schizophrenic Psychoses is dedicated to studying the physiological principles of schizophrenic disorders and developing new treatment options. Its research mainly focusses on the use of clinical-neurophysiological (e.g. TMS, tDCS, surface EMG) and behavioural neuroscience techniques and on performing Phase II to IV clinical studies according to the German drug law (AMG). The group also works on developing and implementing national and international treatment guidelines for the treatment of schizophrenic psychoses, on developing diagnostic algorithms and on the differential diagnosis of organic illnesses in this group of diseases. Below you can find a selection of publications on the work of our group. The Working Group cooperates closely with the Study Centre Psychiatry and the GCBS.


Staff

  • Dr. med. Wolfgang Strube, Doctor
  • Dr. med. Astrid Röh, Doctor, Study investigator
  • Dr. med. Elias Wagner, Doctor, Study investigator
  • Lisa Löhrs, Doctor, Study investigator
  • Tatiana Oviedo, Doctor, Study investigator
  • Dr. med. univ. Tilmann Bunse, Doctor
  • Dr. med. Maximilian Hansbauer, Doctor (currently on a rotation in Regensburg)
  • Nina Filipova, Doctor, Study investigator
  • Dr. med. Jan Häckert, Doctor
  • Camelia Cimpianu, Doctor (currently on a rotation in Department of Forensic Psychiatry)
  • Dr. med. Lucia Bulubas (together with Prof. Dr. med. F. Padberg), Doctor, EKFS Scholarship Holder
  • Irina Papazova, MSc, Psychologist
  • Benjamin Pross, MSc, Psychologist
  • Jana Nolden, Dipl. Psych., Psychologist
  • Melanie Dürkop, BSc, Psychologist
  • Thanh Duyen Tieu, Study support
  • Jennifer Penic, Study support (SPZ)
  • Thomas, Görlitz, Study coordinator (SPZ)

Ongoing projects

  • Efficacy of early administration of clozapine in improving remission rates in acute schizophrenia (EARLY study) (sponsored by the German Research Foundation [DFG]; lead: A. Hasan). More details can be found here.
  • Studies on the effect of nicotinic modulation on cortical excitability, plasticity and cognition in patients with schizophrenia (sponsored by the German Research Foundation [DFG]; lead: A. Hasan). More details can be found here.
  • Randomised controlled study on the effects of spironolactone on cognitive symptoms in people with schizophrenia (sponsored by the Stanley Foundation; lead: A. Hasan). More details can be found here.
  • Treatment of auditory hallucinations in schizophrenia with bilateral theta burst stimulation
    (cooperation with the University of Tübingen; lead: C. Plewnia; sponsored by the German Research Foundation [DFG]). More details can be found here.
  • Randomised controlled study to compare the efficacy of oral and depot antipsychotics in people with schizophrenia (sponsored by EGRIS; lead: A. Hasan). More details can be found here.
  • Study on transcranial random noise stimulation in the treatment of cognitive symptoms in the domain of negative symptoms of schizophrenia (Lead: A. Hasan). More details can be found here.
  • Programme on early intervention in and rehabilitation and integration of people with severe psychotic illnesses (CHANCE) (sponsored by the Robert Vogel Foundation; lead: A. Hasan, P. Falkai). More details can be found here.
  • MEHIRA – Stepped care model to promote mental health in refugees and asylum seekers (cooperation with Charité Berlin; lead: M. Bajbouj); sponsored by the Innovation Fund of the Federal Joint Committee (G-BA). We manage Subproject 4 ’Empowerment‘ together with F. Padberg. More details can be found here.
  • IMPPETUS – Implementation of the patient guideline on psychosocial therapies for patients with severe mental illness (cooperation with the University of Ulm; lead: M. Kösters); sponsored by the Innovation Fund of the Federal Joint Committee (G-BA). We manage Work Package 2. More details can be found here.
  • Prospective and retrospective studies on the appearance of autoimmune antibodies in the serum and cerebrospinal fluid of people with affective and non-affective psychoses.
  • Comparative physiological studies on variability in response to non-invasive brain stimulation in healthy volunteers and people with non-affective psychoses
  • Genome-wide association study (GWAS) on schizophrenia and clozapine (CLOZIN; cooperation with UMC Utrecht; lead: J. Luykx). More details can be found here.
  • Efficacy and mechanisms of transcranial direct current stimulation (tDCS)-enhanced cognitive training in schizophrenia (as a subproject of the Federal Ministry of Education and Research [BMBF] research network ESPRIT, cooperation with the University of Tübingen; lead: C. Plewnia, A. Fallgatter, A. Hasan). More details can be found here.
  • Revision of the WFSBP treatment guideline on the biological treatment of schizophrenia and revision of AWMF/DGPPN S3 guideline for schizophrenia.

Sponsors

Publications

  • This link will take you to an overview of the most important publications of our working group. 

External cooperation partners